TY - JOUR
T1 - In-Stent Restenosis in Saphenous Vein Grafts (from the DIVA Trial)
AU - Xenogiannis, Iosif
AU - Rangan, Bavana V.
AU - Uyeda, Lauren
AU - Banerjee, Subhash
AU - Edson, Robert
AU - Bhatt, Deepak L.
AU - Goldman, Steven
AU - Holmes, David R.
AU - Rao, Sunil V.
AU - Shunk, Kendrick
AU - Mavromatis, Kreton
AU - Ramanathan, Kodangudi
AU - Bavry, Antony A.
AU - McFalls, Edward O.
AU - Garcia, Santiago
AU - Thai, Hoang
AU - Uretsky, Barry F.
AU - Latif, Faisal
AU - Armstrong, Ehrin
AU - Ortiz, Jose
AU - Jneid, Hani
AU - Liu, Jayson
AU - Aggrawal, Kul
AU - Conner, Todd A.
AU - Wagner, Todd
AU - Karacsonyi, Judit
AU - Ventura, Beverly
AU - Alsleben, Aaron
AU - Lu, Ying
AU - Shih, Mei Chiung
AU - Brilakis, Emmanouil S.
N1 - Publisher Copyright:
© 2021
PY - 2022/1/1
Y1 - 2022/1/1
N2 - Saphenous vein grafts (SVGs) have high rates of in-stent restenosis (ISR). We compared the baseline clinical and angiographic characteristics of patients and lesions that did develop ISR with those who did not develop ISR during a median follow-up of 2.7 years in the DIVA study (NCT01121224). We also examined the ISR types using the Mehran classification. ISR developed in 119 out of the 575 DIVA patients (21%), with similar incidence among patients with drug-eluting stents and bare-metal stents (BMS) (21% vs 21%, p = 0.957). Patients in the ISR group were younger (67 ± 7 vs 69 ± 8 years, p = 0.04) and less likely to have heart failure (27% vs 38%, p = 0.03) and SVG lesions with Thrombolysis In Myocardial Infarction 3 flow before the intervention (77% vs 83%, p <0.01), but had a higher number of target SVG lesions (1.33 ± 0.64 vs 1.16 ± 0.42, p <0.01), more stents implanted in the target SVG lesions (1.52 ± 0.80 vs 1.31 ± 0.66, p <0.01), and longer total stent length (31.37 ± 22.11 vs 25.64 ± 17.42 mm, p = 0.01). The incidence of diffuse ISR was similar in patients who received drug-eluting-stents and BMS (57% vs 54%, p = 0.94), but BMS patients were more likely to develop occlusive restenosis (17% vs 33%, p = 0.05).
AB - Saphenous vein grafts (SVGs) have high rates of in-stent restenosis (ISR). We compared the baseline clinical and angiographic characteristics of patients and lesions that did develop ISR with those who did not develop ISR during a median follow-up of 2.7 years in the DIVA study (NCT01121224). We also examined the ISR types using the Mehran classification. ISR developed in 119 out of the 575 DIVA patients (21%), with similar incidence among patients with drug-eluting stents and bare-metal stents (BMS) (21% vs 21%, p = 0.957). Patients in the ISR group were younger (67 ± 7 vs 69 ± 8 years, p = 0.04) and less likely to have heart failure (27% vs 38%, p = 0.03) and SVG lesions with Thrombolysis In Myocardial Infarction 3 flow before the intervention (77% vs 83%, p <0.01), but had a higher number of target SVG lesions (1.33 ± 0.64 vs 1.16 ± 0.42, p <0.01), more stents implanted in the target SVG lesions (1.52 ± 0.80 vs 1.31 ± 0.66, p <0.01), and longer total stent length (31.37 ± 22.11 vs 25.64 ± 17.42 mm, p = 0.01). The incidence of diffuse ISR was similar in patients who received drug-eluting-stents and BMS (57% vs 54%, p = 0.94), but BMS patients were more likely to develop occlusive restenosis (17% vs 33%, p = 0.05).
UR - http://www.scopus.com/inward/record.url?scp=85118645000&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118645000&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2021.09.024
DO - 10.1016/j.amjcard.2021.09.024
M3 - Article
C2 - 34736721
AN - SCOPUS:85118645000
SN - 0002-9149
VL - 162
SP - 24
EP - 30
JO - American Journal of Cardiology
JF - American Journal of Cardiology
ER -